Ownership

Ownership in One Page

Cadila Healthcare (Zydus Lifesciences) maintains an unwavering 69.64% stake in Zydus Wellness with zero promoter pledge risk — a clean ownership structure with no forced-sale risk even under 30% stock declines. [FACT][1] Institutional ownership (FII + DII combined) has contracted ~1pp year-on-year to 22.0%, primarily through DII reduction, while public/retail ownership has grown from 7.83% (Jun 2025) to 8.32% (Mar 2026), suggesting steady retail accumulation despite institutional caution. [FACT][1] The free float is approximately 30.36% of total equity. [AI] Key watch: Q4 FY26 earnings announcement May 18, 2026 will provide first visibility on the ₹3,042 Cr borrowings (up from ₹188 Cr in Mar 2025) incurred largely for the Comfort Click acquisition; any promoter selling to fund this, or further institutional exit, would be a red flag. [FACT][2]

---

Ownership Structure

The shareholding register is dominated by the promoter group (Cadila Healthcare), with modest institutional ownership and growing retail presence. [FACT][1]

Category	Mar 2026 (%)	Jun 2025 (%)	Change (pp)	Type
Promoter	69.64	69.64	0.00	Cadila Healthcare (Zydus Lifesciences)
FII	3.17	3.25	−0.08	Foreign institutional investors
DII	18.87	19.27	−0.40	Domestic mutual funds, insurance, banks
Public/Retail	8.32	7.83	+0.49	Individual shareholders (~80,671 active)

Interpretation: Zydus Wellness is a promoter-controlled company with limited free float (~30%). The free float is adequate for mid-cap institutional fund position sizing but not sufficiently liquid for mega-cap index funds. [AI] Institutional ownership is moderate (~22% combined FII/DII), typical for a ₹16,150 Cr FMCG company. [FACT][1] DII presence (18.87%, mostly domestic mutual funds and insurance) is the primary institutional anchor; FII presence is muted at 3.17%, suggesting overseas funds have limited engagement with the name. [AI]

---

Ownership Trend (Last 8 Quarters)

Trend Analysis:

Ownership movement over the past 2 years reveals three distinct phases:

1. Promoter Accumulation (Jun 2023 – Mar 2024): Cadila raised its stake from 67.11% to 69.62% over 3 quarters, signaling confidence post-Heinz India integration. [FACT][1] DII simultaneously declined from ~22% to ~19% (≈ −3pp), suggesting institutional profit-taking during the accumulation rally. [AI]

2. Stabilization (Mar 2024 – Dec 2025): Promoter stake locked at 69.62–69.64%; FII and DII fluctuated narrowly around 3.3% and 20%, respectively. [FACT][1] Public shareholding contracted before recovering to 8.32% by Mar 2026.

3. Recent Institutional Exit (Mar 2025 – Mar 2026): Both FII and DII reduced holdings over the past 12 months, while public shareholding expanded. [FACT][1] This divergence is consistent with institutional discomfort — likely tied to the heavy borrowing (₹3,042 Cr in Sep 2025 from ₹188 Cr in Mar 2025) and two consecutive quarterly losses in Q2 and Q3 FY26. [AI] DII reduction is the more material concern as mutual funds and insurance companies typically lead early exits from companies facing near-term earnings headwinds.

Key Observation: No material index inclusion/exclusion during this period; shareholding moves are driven by fundamental buying/selling, not passive rebalancing. [AI]

---

Promoter Health

Promoter financial health is the critical risk factor for Indian listed companies. Cadila Healthcare's position in ZYDUSWELL is exceptionally clean. [AI]

Metric	Mar 2026	Dec 2025	Sep 2025	Mar 2025	Trend
Promoter stake (%)	69.64	69.64	69.64	69.64	Stable
Pledged % of holding	0.0	0.0	0.0	0.0	Zero risk
Pledged % of total	0.0	0.0	0.0	0.0	Zero risk

Assessment:

Zero pledge = zero forced-sale risk. Cadila Healthcare has not pledged a single share of its 69.64% stake against loans or margin, meaning there is no lender-enforced sell trigger if ZYDUSWELL stock declines. [FACT][1] This is exceptionally clean for an Indian promoter and suggests either (a) strong balance sheet health at Cadila itself, or (b) conservative capital structure preferences. [AI]

Directional concern: Debt concentration at subsidiary. While the promoter itself is not under pledge stress, ZYDUSWELL's own balance sheet took on ₹3,042 Cr of borrowings as of Sep 2025 (up from ₹188 Cr in Mar 2025) largely to finance the Comfort Click acquisition. [FACT][2] This is roughly a 16× increase in absolute borrowings within a half-year and is the primary near-term financial risk. If ZYDUSWELL cannot service this debt from operating cash flow and the parent does not inject equity, capital-structure stress would pressure the shareholding outlook. Q4 FY26 earnings (May 18, 2026) and FY27 guidance will be decisive for debt serviceability. [AI]

No insider buying recorded during acquisition window. Insider activity files show no insider transactions captured during the Aug-Sep 2025 acquisition window, which is noteworthy. [FACT][3] Typical insider signals (promoter or board buying during accretive M&A) are therefore absent — interpretable as either (a) trading blackout periods, or (b) lack of personal market signaling. [AI]

---

Institutional Footprint

Named institutional holder data is not available in BSE shareholding pattern disclosures (only aggregate FII/DII percentages). [FACT][1]

Entity Type	Est. Stake (%)	Direction
Mutual Funds (DII)	~11–12	Reducing (−0.40pp in last 9mo)
Insurance Companies (DII)	~5–7	Reducing (estimated)
Foreign Funds (FII)	~3.2	Stable-to-slightly-declining
Banks/HNIs (unclassified)	~3–4	Unknown

Gaps: BSE shareholding pattern data (published quarterly) lists only aggregate FII/DII, not named holdings. To identify specific funds would require accessing MF fact sheets or equivalent disclosures not in the staged Dan data. [AI]

---

Supply & Demand Calendar

Known Supply/Demand Events

Event	Type	Timing	Direction	Probability	Impact
Q4 FY26 / FY27 guidance	Earnings Catalyst	May 18, 2026	Demand or Supply	Confirmed	High — earnings surprise and debt guidance will determine if institutions stay or exit
Comfort Click integration progress	Business milestone	H1 FY27 (Jul–Sep 2026)	Demand/Supply	Likely	Medium — execution on acquisition will determine long-term shareholding stability
Dividend announcement (if any)	Capital return	June–Aug 2026 (post-Q4 results)	Demand	Likely	Low — dividend yield likely <1%, immaterial for institutional positioning
Q1 FY27 earnings	Earnings Catalyst	Aug–Sep 2026	Demand/Supply	Confirmed	Medium — early signal on debt trajectory post-acquisition
No lock-up expirations or QIPs identified	—	—	—	N/A	—

Event Risk Assessment

Q4 FY26 earnings (May 18, 2026) is the decisive event. [FACT][4] The market is pricing ZYDUSWELL at elevated TTM P/E multiples (depressed earnings denominator due to recent losses). [AI] Q4 FY26 results will reveal:

• Whether the Comfort Click acquisition is on track to be accretive to earnings;
• Management guidance for FY27 revenue and EBITDA;
• Debt repayment plan (refinancing vs. operating cash paydown);
• Cash flow impact (Comfort Click integration capex).

Scenario sketch:

• Positive: Revenue ≥ ₹700 Cr, EBITDA margin ≥ 13%, debt trajectory improving → Institutional re-entry plausible. [AI]
• Negative: Revenue < ₹650 Cr, EBITDA margin < 10%, debt stable/rising → Further institutional exit risk. [AI]

---

Short Interest and Borrow

Short interest data is not readily available for Indian listed stocks through public disclosures. Unlike US or UK exchanges, Indian NSE does not publish aggregate short interest percentages or days-to-cover metrics. [AI]

Inference: With a ~30% free float and a sizeable retail base, the stock is not in the "borrow shortage" category typical of short squeezes. However, the modest FII/DII presence (22% combined) and heavy promoter weighting (69.64%) reduce the pool of securities available for shorting, which could create local borrow bottlenecks during downturns. [AI]

No short-interest alert applicable.

---

What to Watch

Signal	Why It Matters	Current State	Positive Signal	Negative Signal	Where to Check
Promoter pledge creep	Cadila financial stress would force ZYDUSWELL share sales	0% pledged (clean)	Stays ≤5% of holding	Breaches 20% of holding	BSE shareholding pattern (quarterly), AR promoter disclosures
DII / mutual fund exit	Institutional outflows signal deteriorating fundamentals	18.87% DII (down ~0.9pp in 12mo)	DII stable >19% or adding	DII <17% (further −200bps)	BSE shareholding pattern quarterly
Q4 FY26 earnings surprise	EBITDA and debt guidance determine stock re-rating	Earnings May 18, 2026	Revenue ≥₹700 Cr, margin ≥13%, debt declining	Revenue <₹650 Cr, margin <10%, debt flat/rising	Zydus Wellness investor site, May 18 earnings call
Debt service capacity	₹3,042 Cr borrowings require strong operating cash generation	TTM FCF likely strained	FCF positive by Q2 FY27, debt/EBITDA <3×	FCF negative for 3+ quarters, debt/EBITDA >4×	Q4 FY26 cash flow statement, FY27 guidance
Comfort Click synergy realization	Acquisition was heavily debt-financed; breakeven on debt load depends on synergy capture	Sep 2025 acquisition (early stage)	Revenue synergy ₹50–100 Cr by FY27	Synergy delayed, margin accretion pushed to FY28+	Investor presentations, transcripts Jun/Aug 2026
Public/retail shareholding trend	Growing retail could indicate retail buying on hope, or institutional selling absorbed by retail	Up from 7.83% (Jun 2025), +0.49pp growth to 8.32%	Retail stable or declining	Retail >10% (retail-heavy stocks prone to volatility)	BSE shareholding pattern quarterly
Index inclusion / exclusion	Mid-cap mkt cap could qualify for inclusion in mid-cap indices, triggering passive flows	Not on inclusion watchlist (verified May 2026)	Addition to broad index → passive demand	Removal from index → passive supply	NSE/BSE index methodology, rebalancing schedules
Cadila Healthcare (parent) financial health	Promoter's ability to backstop if subsidiary debt rises	Not monitored directly here	Cadila remains investment-grade credit	Cadila rating downgrade or dividend cut	Zydus Lifesciences ratings, Q4 results

---

Summary

The first ownership signal to watch is the May 18, 2026 Q4 FY26 earnings announcement. [FACT][4] It will be the first material data point on whether the ₹3,042 Cr Comfort Click acquisition debt is sustainable and accretive. [AI] If EBITDA margin compresses and debt service consumes a large share of EBITDA, DII/FII flight could accelerate. Conversely, if management delivers positive surprises on revenue, margin, and debt roadmap, institutional inflow could resume and stabilize ownership at current levels. [AI]

The promoter's zero-pledge stance and stable 69.64% holding provide a floor against sudden dilution or forced sales, but this is a passive backstop, not a growth catalyst. [FACT][1] Institutional shareholding sentiment (FII/DII net flow) will be the live indicator of fundamental confidence over the next 2–4 quarters. [AI]

---

Data as of: March 31, 2026 (latest BSE shareholding pattern) [FACT][1] Price as of: May 14, 2026 (₹507.90) [FACT][5] Market cap: ~₹16,150 Cr [FACT][5] Shareholder base: ~80,671 active shareholders (Mar 2026) [FACT][1]